Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

Luis A. Carvajal, Ulrich G. Steidl

Research output: Contribution to journalShort survey

2 Citations (Scopus)

Abstract

Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.

Original languageEnglish (US)
Pages (from-to)6-8
Number of pages3
JournalCell Stem Cell
Volume19
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Neoplastic Stem Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia
Stem Cells
Cell Survival
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Cite this

Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy. / Carvajal, Luis A.; Steidl, Ulrich G.

In: Cell Stem Cell, Vol. 19, No. 1, 01.07.2016, p. 6-8.

Research output: Contribution to journalShort survey

@article{7578e406a791435788c85222f3e56241,
title = "Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy",
abstract = "Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.",
author = "Carvajal, {Luis A.} and Steidl, {Ulrich G.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.stem.2016.06.005",
language = "English (US)",
volume = "19",
pages = "6--8",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

AU - Carvajal, Luis A.

AU - Steidl, Ulrich G.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.

AB - Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.

UR - http://www.scopus.com/inward/record.url?scp=85008601750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008601750&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2016.06.005

DO - 10.1016/j.stem.2016.06.005

M3 - Short survey

C2 - 27392220

AN - SCOPUS:85008601750

VL - 19

SP - 6

EP - 8

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 1

ER -